Author Email: email@example.com
Mistletoe extract use in cancer patients is widely increasing with the upsurge of cancer incidence rates and reduction in survival time of patients. This study was designed to assess the tumor regression in breast cancer patients with the mistletoe extract. Subjects were designated from outpatient clinic at Rishikesh Hospital, Nashik, INDIA. After giving written informed consent, participants completed a self-administered questionnaire. Twelve patients with histologically confirmed breast cancer tumors of at least 2 cm in diameter received mistletoe extract in an ascending dosage. The tumour was again measured after six months to assess the therapeutic potential of mistletoe extract. The median size of the tumour decreased significantly, from 3.8 cm (range, 1 to 8 cm) to 2 cm (range, 0.1 to 4.8 cm; P < 0.001) on physical examination. Sonographic measurement revealed that, the tumour median size was significantly decreased from 3 cm (range, 0 to 8 cm) to 1.5 cm (range, 0 to 4 cm; P < 0.001). The area of tumour was significantly decreased on physical measurement and sonographic measurement (P < 0.001). The positive nodal status decreased from 66.6 to 41.6 percentages of patients. Mistletoe extract is highly effective and provides a feasible therapeutic option to the clinical oncologist in tumour regression of breast cancer.
Breast cancer is one of the most extensively prevalent cancer in women, which accounts almost 30 % of all cancers (Ries et al., 2001). Breast cancer is the most common type of non-cutaneous malignancy in women in the United States (Greene et al., 2002). Globally, US, India and China accounts almost one third of the breast cancer burden. In India, the incidence rate of breast cancer increasing rampantly. A statistical trend of breast cancer was compared in India with western nations like the US and with neighbour, China. In year 2012, the incidence to mortality ratio was high in India, almost three times higher than US and two times higher than China. The breast cancer burden in India has almost
reached about two third of that of the US and is steadily rising (IARC, 2012). Breast cancer survival is robustly associated with tumour size detection at initial stages of the disease (Okugawa et al., 2005; Michaelson et al., 2002; Jayasinghe et al., 205). Taking into an account of various factors like physical, emotional, and financial impacts allied with disease, it is prudent to diagnose with greatest accuracy. Tumour size pivots a major role in determining disease-free and cause-specific survival in invasive breast cancer particularly, in cases of node-negative breast cancers.
Breast tumours are pathologically classified into groups for staging purpose, because accurate measurement of the tumour is decisive for management of best outcomes. Measuring tumour size is one of the most conventional technique for monitoring cancer development with response to treatment in oncology. Tumour size is measured by various methods including palpation on physical examination and breast-imaging studies such as mammography, sonography and MRI. In this present study, tumour size of patients before and after treatment was measured by physical examination and sonography.
Mistletoe extract is also known as European mistletoe (Viscum album) and used as cancer therapy based on anthroposophy (Steiner et al., 1985). However, mistletoe extract is considered as complementary medicine, it is most commonly used in oncological medicine (Schwabe et al., 1998). Mistletoe extract management in cancer is evidenced from a plethora of clinical studies. Quality of life and survival of cancer patients significantly increased with mistletoe in cancer patients was reported in various studies (Sandeep roy, 2014; Semiglazov et al., 2006; Piao et al., 2004; Kim et al., 2012; Semiglazov et al., 2004). The present investigation was carried out to determine the effects of mistletoe extract in breast cancer patients.
109 total views, 3 views today